|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ferlay J, Colombet M, Soerjomataram I,
Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer
incidence and mortality patterns in Europe: Estimates for 40
countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387.
2018.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Van Cutsem E, Cervantes A, Adam R, Sobrero
A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson
A, Bodoky G, et al: ESMO consensus guidelines for the management of
patients with metastatic colorectal cancer. Ann Oncol.
27:1386–1422. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Andre T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt CJA, Smith DM, Garcia-Carbonero R, Benavides M,
Gibbs P, et al: Pembrolizumab versus chemotherapy for
microsatellite instability-high/mismatch repair deficient
metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. J Clin
Oncol. 38 (Suppl 18)(LBA4)2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Giantonio BJ, Catalano PJ, Meropol NJ,
O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III:
Eastern Cooperative Oncology Group Study E3200. Bevacizumab in
combination with oxaliplatin, fluorouracil, and leucovorin
(FOLFOX4) for previously treated metastatic colorectal cancer:
Results from the eastern cooperative oncology group study E3200. J
Clin Oncol. 25:1539–1544. 2007.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Van Cutsem E, Rivera F, Berry S,
Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL,
Georgoulias V, Peeters M, et al: Safety and efficacy of first-line
bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in
metastatic colorectal cancer: The BEAT study. Ann Oncol.
20:1842–1847. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Van Cutsem E, Lenz HJ, Köhne CH, Heinemann
V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken
JH and Ciardiello F: Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J Clin
Oncol. 33:692–700. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Petrelli F, Tomasello G, Borgonovo K,
Ghidini M, Turati L, Dallera P, Passalacqua R, Sgroi G and Barni S:
Prognostic survival associated with left-sided vs right-sided colon
cancer: A systematic review and meta-analysis. JAMA Oncol.
3:211–219. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Guinney J, Dienstmann R, Wang X, de
Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda
G, Angelino P, et al: The consensus molecular subtypes of
colorectal cancer. Nat Med. 21:1350–1356. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
10
|
Yaeger R, Chatila WK, Lipsyc MD, Hechtman
JF, Cercek A, Sanchez-Vega F, Jayakumaran G, Middha S, Zehir A,
Donoghue MTA, et al: Clinical sequencing defines the genomic
landscape of metastatic colorectal cancer. Cancer Cell.
33:125–136.e3. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Koboldt DC, Zhang Q, Larson DE, Shen D,
McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK:
VarScan 2: Somatic mutation and copy number alteration discovery in
cancer by exome sequencing. Genome Res. 22:568–576. 2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES
and Getz G: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Kim S, Scheffler K, Halpern AL, Bekritsky
MA, Noh E, Källberg M, Chen X, Kim Y, Beyter D, Krusche P and
Saunders CT: Strelka2: Fast and accurate calling of germline and
somatic variants. Nat Methods. 15:591–594. 2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Nykamp K, Anderson M, Powers M, Garcia J,
Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M, et
al: Sherloc: A comprehensive refinement of the ACMG-AMP variant
classification criteria. Genet Med. 19:1105–1117. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hundal J, Carreno BM, Petti AA, Linette
GP, Griffith OL, Mardis ER and Griffith M: pVAC-Seq: A
genome-guided in silico approach to identifying tumor neoantigens.
Genome Med. 8(11)2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Warren RL, Choe G, Freeman DJ, Castellarin
M, Munro S, Moore R and Holt RA: Derivation of HLA types from
shotgun sequence datasets. Genome Med. 4(95)2012.PubMed/NCBI View
Article : Google Scholar
|
|
17
|
Ha G, Roth A, Khattra J, Ho J, Yap D,
Prentice LM, Melnyk N, McPherson A, Bashashati A, Laks E, et al:
TITAN: Inference of copy number architectures in clonal cell
populations from tumor whole-genome sequence data. Genome Res.
24:1881–1893. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Rosenthal R, McGranahan N, Herrero J,
Taylor BS and Swanton C: DeconstructSigs: Delineating mutational
processes in single tumors distinguishes DNA repair deficiencies
and patterns of carcinoma evolution. Genome Biol.
17(31)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Alexandrov LB, Nik-Zainal S, Wedge DC,
Campbell PJ and Stratton MR: Deciphering signatures of mutational
processes operative in human cancer. Cell Rep. 3:246–259.
2013.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Macintyre G, Goranova TE, De Silva D,
Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson
C, et al: Copy number signatures and mutational processes in
ovarian carcinoma. Nat Genet. 50:1262–1270. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Middha S, Zhang L, Nafa K, Jayakumaran G,
Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, et al:
Reliable pan-cancer microsatellite instability assessment by using
targeted next-generation sequencing data. JCO Precis Oncol.
2017(PO.17.00084)2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sztupinszki Z, Diossy M, Krzystanek M,
Reiniger L, Csabai I, Favero F, Birkbak NJ, Eklund AC, Syed A and
Szallasi Z: Migrating the SNP array-based homologous recombination
deficiency measures to next generation sequencing data of breast
cancer. NPJ Breast Cancer. 4(16)2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z,
Meirelles GV, Clark NR and Ma'ayan A: Enrichr: Interactive and
collaborative HTML5 gene list enrichment analysis tool. BMC
Bioinformatics. 14(128)2013.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lausen B, Hothorn T, Bretz F and
Schumacher M: Assessment of optimal selected prognostic factors.
Biom J. 46:364–374. 2004.
|
|
25
|
Hothorn T and Lausen B: On the exact
distribution of maximally selected rank statistics. Comput Stat
Data Anal. 43:121–137. 2003.
|
|
26
|
Takaya H, Nakai H, Takamatsu S, Mandai M
and Matsumura N: Homologous recombination deficiency status-based
classification of high-grade serous ovarian carcinoma. Sci Rep.
10(2757)2020.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Cancer Genome Atlas Network. Comprehensive
molecular characterization of human colon and rectal cancer.
Nature. 487:330–337. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Zaidi SH, Harrison TA, Phipps AI,
Steinfelder R, Trinh QM, Qu C, Banbury BL, Georgeson P, Grasso CS,
Giannakis M, et al: Landscape of somatic single nucleotide variants
and indels in colorectal cancer and impact on survival. Nat Commun.
11(3644)2020.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Franko J, Shi Q, Goldman CD, Pockaj BA,
Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR and Sargent
DJ: Treatment of colorectal peritoneal carcinomatosis with systemic
chemotherapy: A pooled analysis of north central cancer treatment
group phase III trials N9741 and N9841. J Clin Oncol. 30:263–267.
2012.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Boeckx N, Koukakis R, Op de Beeck K, Rolfo
C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T and
Peeters M: Primary tumor sidedness has an impact on prognosis and
treatment outcome in metastatic colorectal cancer: Results from two
randomized first-line panitumumab studies. Ann Oncol. 28:1862–1868.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ghiringhelli F, Hennequin A, Drouillard A,
Lepage C, Faivre J and Bouvier AM: Epidemiology and prognosis of
synchronous and metachronous colon cancer metastases: A French
population-based study. Dig Liver Dis. 46:854–858. 2014.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pennington KP, Walsh T, Harrell MI, Lee
MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord
AS, et al: Germline and somatic mutations in homologous
recombination genes predict platinum response and survival in
ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer
Res. 20:764–775. 2014.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Zhao EY, Shen Y, Pleasance E, Kasaian K,
Leelakumari S, Jones M, Bose P, Ch'ng C, Reisle C, Eirew P, et al:
Homologous recombination deficiency and platinum-based therapy
outcomes in advanced breast cancer. Clin Cancer Res. 23:7521–7530.
2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Bylsma LC, Gillezeau C, Garawin TA, Kelsh
MA, Fryzek JP, Sangaré L and Lowe KA: Prevalence of RAS and BRAF
mutations in metastatic colorectal cancer patients by tumor
sidedness: A systematic review and meta-analysis. Cancer Med.
9:1044–1057. 2020.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wasserman I, Lee LH, Ogino S, Marco MR, Wu
C, Chen X, Datta J, Sadot E, Szeglin B, Guillem JG, et al: SMAD4
loss in colorectal cancer patients correlates with recurrence, loss
of immune infiltrate, and chemoresistance. Clin Cancer Res.
25:1948–1956. 2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Manzat Saplacan RM, Balacescu L, Gherman
C, Chira RI, Craiu A, Mircea PA, Lisencu C and Balacescu O: The
Role of PDGFs and PDGFRs in colorectal cancer. Mediators Inflamm.
2017(4708076)2017.PubMed/NCBI View Article : Google Scholar
|
